BioCentury | Oct 24, 2011
Company News

LCT, Otsuka Pharmaceutical deal

...a 50/50 JV, to be named Diatranz Otsuka Ltd., to develop and commercialize Living Cell's DiabeCell...
...New Zealand. Living Cell will contribute A$25 million in assets and working capital related to DiabeCell...
...to grant Otsuka rights to develop and commercialize DiabeCell in Japan and other Asian countries. DiabeCell...
BioCentury | Apr 18, 2011
Company News

LCT, Otsuka Pharmaceutical deal

...to develop and commercialize Living Cell's DiabeCell in Japan and other Asian countries, excluding China. DiabeCell...
...Ltd. (Nanjing, China) receive a right to first refusal to negotiate exclusive commercialization rights for DiabeCell...
BioCentury | Mar 21, 2011
Company News

Jiangsu Aosaikang Pharmaceutical Co. Ltd., LCT deal

...right to first refusal to negotiate exclusive commercialization rights for Living Cell's DiabeCell in China. DiabeCell...
BioCentury | Nov 15, 2010
Clinical News

DiabeCell: Interim Phase II data

...from 4 patients in an ongoing, dose-ranging, New Zealand Phase II trial showed that 1 DiabeCell...
...of 10,000 islet equivalents/kg reduced the severity of hypoglycemic events by 64% at week 24. DiabeCell...
...DiabeCell implants of 20,000 islet equivalents/kg. Living Cell Technologies Ltd. (ASX:LCT; OTCQX:LVCLY), Sydney, Australia Product: DiabeCell...
BioCentury | Aug 9, 2010
Clinical News

DiabeCell: Phase II expanded

...Phase II trial evaluating Diabecell implants. Living Cell Technologies Ltd. (ASX:LCT; OTCQX:LVCLY), Sydney, Australia Product: DiabeCell...
BioCentury | May 3, 2010
Finance

Regulatory Milestones

...the Juvenile Diabetes Research Foundation International for an on-going New Zealand Phase I/II trial testing DiabeCell...
BioCentury | Apr 12, 2010
Clinical News

DiabeCell: Additional Phase I/IIa data

...Additional data from a Russian Phase I/IIa trial in 8 patients showed that DiabeCell implant reduced...
...reduced daily insulin by 13-100% at 6 months. In 5 patients receiving a second implant, DiabeCell...
...reduced daily insulin by 10-25% at 12 months. In 4 patients receiving a third implant, DiabeCell...
BioCentury | Apr 5, 2010
Clinical News

DiabeCell: Phase I/IIa ongoing

...first 4 patients, a DSMB recommended continuation of a New Zealand Phase I/IIa trial of DiabeCell...
...10,000 in the first 4 patients. Living Cell Technologies Ltd. (ASX:LCT; OTCQX:LVCLY), Sydney, Australia Product: DiabeCell...
BioCentury | Dec 14, 2009
Clinical News

DiabeCell: Interim Phase I/IIa data

...Zealand Phase I/IIa trial showed that the daily insulin dose for 1 patient receiving the DiabeCell...
...enroll 8 patients in the trial. Living Cell Technologies Ltd. (ASX:LCT; OTCQX:LVCLY), Sydney, Australia Product: DiabeCell...
BioCentury | Jul 27, 2009
Clinical News

DiabeCell: Phase I/IIa started

...Living Cell Technologies began an open-label, dose-escalation, New Zealand Phase I/IIa trial to evaluate DiabeCell implant...
...8 patients with poorly controlled diabetes. Living Cell Technologies Ltd. (ASX:LCT; OTCQX:LVCLY), Sydney, Australia Product: DiabeCell...
Items per page:
1 - 10 of 22